In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...